Large-scale virtual screening for discovering leads in the postgenomic era

Virtual screening, or in silico screening, is a new approach attracting increasing levels of interest in the pharmaceutical industry as a productive and cost-effective technology in the search for novel lead compounds. Although the principles involved--the computational analysis of chemical databases to identify compounds appropriate for a given biological receptor--have been pursued for several years in molecular modeling groups, the availability of inexpensive high-performance computing platforms has transformed the process so that increasingly complex and more accurate analyses can be performed on very large data sets. The virtual screening technology of Protherics Molecular Design Ltd. is based on its integrated software environment for receptor-based drug design, called Prometheus. In particular, molecular docking is used to predict the binding modes and binding affinities of every compound in the data set to a given biological receptor. This method represents a very detailed and relevant basis for prioritizing compounds for biological screening. This paper discusses the broader scope of virtual screening and, as an example, describes our recent work in docking one million compounds into the estrogen hormone receptor in order to highlight the technical feasibility of performing very large-scale virtual screening as a route to identifying novel drug leads.